Lataa...
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Landes Bioscience
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3494633/ https://ncbi.nlm.nih.gov/pubmed/23170267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20591 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|